NCT04812028View on ClinicalTrials.gov

Magnesium Sulfate for Analgesia in Pediatric Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

August 10, 2023

Study Completion Date

August 10, 2023

Conditions
Postoperative Pain
Interventions
DRUG

Magnesium sulfate

Magnesium sulfate (MgSO4) will be administered intravenously at induction of anesthesia as a 30-minute bolus dose of 50 mg/kg (maximum 2 grams) in the OR, followed by a 15 mg/kg/hr IV infusion for 48 hours or once the patient has transferred out of the PICU, whichever comes first.

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT04812028 - Magnesium Sulfate for Analgesia in Pediatric Transplant | Biotech Hunter | Biotech Hunter